Evidence map›Paper›PMID 33678195›Full record

ArticleJournal of pharmaceutical policy and practice2021

Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?

Zuzaan Zulzaga, Erdenetuya Myagmarsuren, Herman J Woerdenbag, Eugene P van Puijenbroek

Abstract readLetter
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zuzaan ZulzagaAssociation of Mongolian Pharmacy Professionals, Apart # 88-33, 25th khoroo, Bayanzurkh District, Ulaanbaatar, Mongolia.ORCID http://orcid.org/0000-0002-3835-4969
Erdenetuya MyagmarsurenDepartment of Clinical Pharmacy and Management, School of Pharmacy, Mongolian National University of Medical Sciences, Ard Ayush street, 6th khoroo, Bayangol district, P.O.Box-188, Ulaanbaatar, Mongolia. erdenetuya.m@mnums.edu.mn.ORCID http://orcid.org/0000-0002-9519-9010
Herman J WoerdenbagDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-9450-5880
Eugene P van PuijenbroekPharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and international safety data. In Mongolia, adverse drug reaction (ADR) reporting activities have been implemented in the past decade. During this period, the basic structure and legal basis of an adverse drug reaction monitoring system was established. Because of the fragmented but growing healthcare system and the complexity of pharmaceutical issues in Mongolia, a sustainable process for the development of the adverse drug reaction reporting system is a key issue. The aim of this article is to disclose the Mongolian situation for the rest of the world and to share experiences on how an ADR reporting system can be developed towards a higher and more advanced level to contribute to both national and international drug safety issues. In this article, we review the features of the Mongolian health care and pharmaceutical systems, as well as the current development of the adverse drug reaction reporting system.

Indexed as

Adverse drug reactionMedicines safetyMongolia

Identifiers

PMID33678195
PMCPMC7938544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.